No black box warning on record for Cnj-016

As of the latest FDA labeling reviewed, Cnj-016 (VACCINIA IMMUNE GLOBULIN INTRAVENOUS (HUMAN)) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cnj-016 medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity to human immune globulin (acute anaphylaxis) ( 5.1 ) • Acute renal dysfunction/failure ( 5.2 ) • Thrombosis may occur with immune globulin products, including VIGIV. For patients at risk of thrombosis, administer VIGIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and s

No black box warning on record for Cnj-016

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity to human immune globulin (acute anaphylaxis) ( 5.1 ) • Acute renal dysfunction/failure ( 5.2 ) • Thrombosis may occur with immune globulin products, including VIGIV. For patients at risk of thrombosis, administer VIGIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and s

Cnj-016 Black Box Warning

No black box warning on record for Cnj-016

Other warnings & precautions

Cnj-016 Black Box Warning

No black box warning on record for Cnj-016

Other warnings & precautions